How many investments has Forbion made?

Forbion has 48 tracked investments, 3 of which have exited, including 14 dated in the last 24 months.

What stage does Forbion invest at?

Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is Forbion located?

Forbion is headquartered in Naarden, NL.

Does Forbion lead rounds?

Forbion has led 10 of the 22 rounds where its role is on record.

Who does Forbion co-invest with?

Forbion most often shares deals with BioMedPartners, DeepTech & Climate Fonds, Entrepreneur First, among 11 tracked co-investors.

Forbion

Venture capitaloperating company · company profile

Naarden · Pre-Seed–Late Stage · 23 people tracked

Also known as FCPM III SERVICES B.V. · FORBION NORTH AMERICA LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Forbion

2,593 people in our graph share verified history with the Forbion team — schools, employers, funds. One of them is your warm intro.

Iris Wiggersunlockedknows Geert-Jan Mulder · together at ABN AMRO Bank N.V. (overlapped)

×11knows the team · via Index Ventures

✨ Fox Verdict

Investment thesis

Forbion invests in groundbreaking biotech and other sustainable solutions that improve the health of people and the planet, structured around human health and planetary health themes. The firm integrates ESG principles into its investments, emphasizing patient impact, societal benefits, and sustainability. It manages a family of funds spanning venture, growth, and bioeconomy strategies, backing companies working on rare disease therapies, novel treatments, and sustainable technologies such as plant-based metal extraction.

Invests inAgTech Biotech Cleantech Climate Tech Healthtech Impact & Social Good Medical Devices Amsterdam Europe Germany Global Netherlands North America United States

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Late Stage

Naarden, MA, NL

Instruments

Equity

Founded

1999

Last 12 months

10 investments

AUM

$5.4B

VC funds

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 23 people

from the firm's website & public directories

Geert-Jan Mulder· Co-founding Managing Partner· Naarden, Netherlandsin

Geert-Jan Mulder is a co-founding Managing Partner at Forbion who has led investments across Europe and the US and works with portfolio company management teams on clinical development strategy and regulatory matters such as IND/NDA filings and orphan designations. Before Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences from 2001, and earlier held roles in the pharmaceutical industry at Byk Gulden (now Takeda) as Clinical Research Manager and at Searle (now Pfizer) as Medical Adviser. He holds a Medical Degree from the University of Utrecht and completed two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.

Martien van Osch· Managing Partner, CFO and co-founder· Boston, MAin 𝕏

Martien van Osch is Managing Partner, CFO and co-founder of Forbion, where he leads the firm's US office in Boston and sits on the Ventures and Growth investment committee. He represented Forbion in Asia from Singapore between 2018 and 2023 and previously led the firm's Fund I-III medical technology investments. Before co-founding Forbion in 2006, he spent six years as an Investment Director at ABN AMRO Capital Life Sciences and holds a degree in Econometrics from the Rijksuniversiteit Groningen.

Alexander Hoffmann· General Partner· Amsterdam Areain

Alexander Hoffmann is a General Partner at Forbion, where he set up and co-led the BioEconomy strategy. He previously was Managing Director at a family office joint-venture focused on early-stage bio-based climate startups, and began his venture career at M Ventures, the venture arm of Merck KGaA, covering Frontier Tech & Sustainability investments spanning digital healthcare and biotech. Earlier, he worked as an operator in tech startups and led Merck's digital strategy for its Africa operations from Nairobi, Kenya.

Dirk Kersten· Managing Partner· Amsterdam, Netherlandsin

Dirk Kersten is a Managing Partner at Forbion, which he joined in 2018, where he manages the Forbion Growth Opportunities Fund. Trained as a physicist, he previously served as a Partner at Gilde Healthcare Partners, leading its Boston office, and as a Managing Director at INKEF Capital overseeing healthcare investments. His work spans fund management, deal making, portfolio management, and exit strategies.

Dmitrij Hristodorov· General Partner· Munich, Germanyin

Dmitrij Hristodorov is a General Partner at Forbion, where his portfolio spans multiple stages, treatment modalities, and disease areas. He previously held R&D Ophthalmology and Business Development roles at Bayer Pharma. He earned a PhD from the University of Aachen (RWTH) in 2013 for immunology work conducted at the Fraunhofer Institute.

Jasper Bos· General Partner· Naarden, Netherlandsin

Jasper Bos is a General Partner at Forbion's Growth Fund. He previously served as Senior Vice President and Managing Director at M Ventures, Merck's venture arm, which he joined in 2009, where he led a team of investment professionals managing a €400 million fund across more than 50 biotech, life sciences tools, and tech companies. He holds a PhD in Pharmacy from the University of Groningen.

Jon Edwards· General Partner· Bostonin

Jon Edwards is a General Partner at Forbion who works on sourcing, evaluating, and structuring investments spanning company creation through early clinical development across therapeutic areas. He joined Forbion in 2025 and was previously a founding team member at Red Tree Venture Capital and Medicxi, with earlier roles at ClearView Healthcare Partners and Sepracor. He completed postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

Joy Faucher· General Partner· Netherlandsin

Joy Faucher is a General Partner at Forbion, which he joined in 2023 to establish and co-lead the firm's BioEconomy strategy. He previously invested in growth and early-stage companies at Lightrock and MVentures (Merck's corporate venture arm), and held operational roles at Formo and Eli Lilly's biotech commercial launch facility. He holds a Master's in Bioscience Enterprise from the University of Cambridge and a Bachelor's in Biochemical Engineering from University College London.

Marco Boorsma· General Partner· Amsterdam, Netherlandsin

Marco Boorsma is a General Partner at Forbion, which he joined in 2007. Before Forbion, he was Business Development Director at DSM Pharmaceutical Products and worked on manufacturing processes for biosimilars at Cytos Biotechnology. He focuses on biotechnology, operations, and business development, with an emphasis on founding and managing new companies as part of Forbion's build strategy, and holds an MSc in Molecular Biology from the University of Groningen and a PhD in Biotechnology from ETH Zürich.

Nanna Lüneborg· General Partner· Amsterdam Areain

General Partner at Forbion, holds a PhD and MBA.

Robbert van de Griendt· General Partner· The Netherlandsin

Robbert leads fundraising and investor relations at BGV and heads Forbion's ESG and impact investing efforts. He previously founded Accretion Capital Partners and was a partner at Virage Capital and Neotech Capital, with over 20 years of experience across Asia, Europe, and North America, and holds a Business Economics degree from Erasmus University Rotterdam.

r•••@biogeneration.vcreveal

Rogier Rooswinkel· General Partner· Naardenin

Rogier Rooswinkel is a General Partner at Forbion's Naarden office, which he joined in 2013, where he evaluates and structures new investment opportunities across disease areas with a focus on oncology. Before Forbion, he was a post-doctoral researcher at the Netherlands Cancer Institute (NKI) in the division of immunology, and during his studies he worked as an independent website designer and founded an IT company. He earned a PhD Cum Laude from the University of Amsterdam in 2013 for work at the NKI, and holds a Master's degree in Oncology from VU University Amsterdam.

Sander Slootweg· Managing Partner· Netherlandsin

Sander Slootweg is Managing Partner at Forbion, which he co-founded in 2006 after co-founding ABN AMRO Capital/Life Sciences in 2000. His earlier roles at ABN AMRO Bank included buy-out and growth equity investing, equity capital markets syndications, and financial institutions relationship management for Latin America. He holds degrees in Business and Financial Economics from the Free University of Amsterdam and in Business Administration from Nyenrode University, and focuses on life sciences investing.

Wouter Joustra· General Partner· Amsterdam, Netherlandsin

Wouter Joustra is a General Partner at Forbion, which he joined in 2019, where he works on deal origination, portfolio management, and divestment strategies with a focus on the firm's Growth Opportunities Funds targeting late-stage life sciences companies. He previously served as a Senior Trader and Executive Board member of the life sciences franchise at the investment bank Kempen. He holds an M.Sc. in Business Administration and a B.Sc. in International Business and Management, both from the University of Groningen.

Holger Reithinger· General Partner· Munich, Germanyin 𝕏

Nanna Luneborg· General Partner· Denmarkin

Antoine Boulanger Piette· Principal· Amsterdam, Netherlands

Audrey Cacaly· Principal· Netherlandsin

Philip Astley-Sparke· Venture Partner· Boston, Massachusettsin

Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.

Carlo Incerti· Operating Partner· Jupiter, Florida, United States

Machteld Groeneveld· Legal Counsel and Compliance Officer· Amsterdam, North Holland, Netherlandsin

Machteld Groeneveld joined Forbion in June 2020 and is responsible for Legal, Risk and Compliance. She serves on the board of the Manager of the Forbion funds as Secretary, and is a member of the firm's Valuation Committee and Responsible Investing Committee. Before Forbion she held legal and strategic roles at multinational and publicly listed companies, focusing on European legal affairs, fund compliance, corporate strategy, and value creation through M&A. She holds an LLM from the University of Utrecht, a postgraduate degree in International Contracting from Grotius Academy, and an Executive MBA from RSM Erasmus University.

Alice Vickers· Advisor· United Kingdomin 𝕏

Marc-Olivier Turgeon· Senior Associate· Amsterdam, Netherlandsin

What they invest in

from 45 of 48 portfolio companies

Biotech ×40Healthtech ×22Medical Devices ×18Deep Tech ×8Digital Health ×8AI & Machine Learning ×7SaaS ×3Cleantech ×2

HQs:United States×15United Kingdom×4Germany×3Netherlands×3Switzerland×1Colombia×1

Investments · 48 tracked

founders shown can be your intro path

By year:2026 · 7 2025 · 5 2024 · 6 2023 · 3 2022 · 1 2021 · 2 2020 · 3 2017 · 1 2015 · 1 2012 · 130 dated

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020SEC filingmedium confidence

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(Chief Executive Officer and President, Director)in

Board seat Dirk Kersten· per SEC Form D · $115.7M raise · filed Aug 2020

Co-investorsAtlas Venture MPM BioImpact Vida Ventures Hercules Capital, Inc.RA Capital

MapLight TherapeuticsNASDAQ: MPLTJul 2025SEC filingmedium confidence

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)inJames Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)in

Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025

Co-investorsNovo Holdings

Azafarosazafaros.com✓ verified

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBioMedPartners Jeito Capital BioGeneration Ventures Pictet Group Seroba Life Sciences

Beacontxbeacontx.com in 𝕏✓ verified

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

Daniel Chung(Chief Medical Officer)in Lance Baldo(Chief Executive Officer)in Abraham Scaria(Chief Scientific Officer)in

Co-investorsAdvent Life Sciences Oxford Science Enterprises TCG Crossover

CatalYmcatalym.com inNov 2020✓ verified

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)in Stefan Ries(Chief Scientific Officer and Head of Munich Site)in Andrea Goddard(Chief Technical Officer)in

Co-investorsJeito Capital Bioqube Ventures Bayern Kapital Canaan Partners Novartis Venture Fund BioGeneration Ventures +1 more

Citryllcitryll.com in✓ verified

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

Renato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsPureos Bioventures BioGeneration Ventures Johnson & Johnson Innovation – JJDC Seventure Partners BOM Curie Capital +1 more

Elevaraelevara.com inOct 2025 · $70M✓ verified

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))in Mai-Britt Zocca(CEO)in

Co-investorsMonograph Capital Partners Sofinnova Partners

Engrail Therapeuticsengrail.com in✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite Capital Longwood Fund Norwest Venture Partners RiverVest Venture Partners Ysios Capital abrdn plc +4 more

Expeditiontxexpeditiontx.com in✓ verified

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)

Co-investorsNovo Holdings Sofinnova Ventures Sanofi Ventures

Gate Biogatebio.com✓ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsVersant Ventures Andreessen Horowitz ARCH Venture Partners GV (Google Ventures)

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)in

Co-investorsNovartis Venture Fund Sanofi Ventures Versant Ventures

Kynexiskynexistx.com in 𝕏✓ verified

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)inKees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios Capital Novartis Venture Fund Sunstone Capital

Mestagmestagtherapeutics.com in 𝕏✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)in

Co-investorsSV Health Investors GV (Google Ventures)Northpond Ventures

Mestag Therapeuticsmestagtx.com in 𝕏Mar 2026 · $40M✓ verified

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGV (Google Ventures)Johnson & Johnson Innovation – JJDC Northpond Ventures SV Health Investors JJDC

Omeicos Therapeuticsomeicos.com in 𝕏✓ verified

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)in Karen Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRemiges Ventures, Inc.Vesalius Biocapital Partners

Pheontxpheontx.com in✓ verified

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Biotechnology Value Fund Lightspeed Venture Partners Research Corporation Technologies TCG Crossover

Purespringpurespringtx.com in 𝕏Oct 2024✓ verified

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

Moin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSofinnova Partners Gilde Healthcare Advent Life Sciences British Patient Capital

SynOx Therapeutics Ltdsynoxtherapeutics.com in 𝕏Nov 2020✓ verified

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

Ray Barlow(Chief Executive Officer)in

Co-investorsHealthCap Bioqube Ventures Gimv Medicxi

ロゴマーク：AIRNAairna.com inSep 2021✓ verified

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

Thorsten Stafforst(Chairman of the Board of Directors)in Kris Elverum in Todd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+ND Capital ARCH Venture Partners Venrock Fast Track Initiative Nextech Invest Novalis LifeSciences +2 more

Exosome Diagnostics inJun 2015SEC filingmedium confidence

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)in

Board seat Geert-Jan Mulder· per SEC Form D · $2.2M raise · filed Jul 2015

Co-investorsArcus Ventures NGN Capital

Milestone Pharmaceuticalsmilestonepharma.com in 𝕏Jul 2017SEC filingmedium confidence

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seat Marco Boorsma· per SEC Form D · $6.9M raise · filed Jul 2017

Co-investorsPappas Capital RTW Investments L.P.

Altesa BioSciencesaltesabio.comFeb 2026 · $75M

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

John Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

Board Nicholas Williams(Director)Moncef Slaoui(Director)Jon Edwards(Director)in

Co-investorsGRA Venture Medicxi Pitango

Amphistaamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)in Giles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life Sciences Novartis Venture Fund SV Health Investors Dementia Discovery Fund European Investment Fund Gilde Healthcare +2 more

Anetaaneta.companyMay 2023

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPebblebed Andera Partners BGV Fountain Healthcare Partners HTGF PMV +2 more

Calluna Pharmacallunapharma.com inJan 2024 · $81M

Completed patient enrollment in its Phase 2 AURORA trial.

Co-investorsP53 Invest Sarsia Management AS Investinor

Complement Therapeuticscomplementtx.comApr 2023

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)in Muhammad Ali Memon(Chief Medical Officer)in

Co-investorsCambridge Innovation Capital Hadean Ventures Seroba Life Sciences BGV BioGeneration Ventures Gimv +1 more

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)in Marie De Vulder(Chief Legal Officer Co-founder)in Guy Peeters(Chief Financial Officer Co-founder)in John-Paul Gallivan(Head of Development Co-founder)in Fabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsLongwood Fund Sofinnova Ventures BAM Elevate Finchley Healthcare Ventures Luma Group Novo Holdings +1 more

F2Gf2g.com

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Brace Pharma Sofinnova Partners +3 more

Forbion Capitalforbion.com

A venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.

AgTechBiotechCleantechClimate TechImpact & Social GoodAmsterdam, NL

Co-investorsBOM KfW Capital

Genominesgenomines.com in

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

Fabien Koutchekian(CEO)in Dali Rashid(CTO)in

Co-investorsCarbon DeepTech & Climate Fonds Entrepreneur First LOWERCARBON Lowercarbon Capital STATION F +6 more

Inversagoinversago.comOct 2022 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAmorChem Genesys Capital JDRF T1D Fund New Enterprise Associates (NEA)Tarnagulla Ventures adMare BioInnovations +2 more

LoQus23loqus23.com inOct 2024

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)in Caroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture Fund SV Health Investors Dementia Discovery Fund

Mariana Oncologymarianaoncology.com in 𝕏Sep 2023 · $175M

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess Biotechnology Atlas Venture Nextech Invest RA Capital

MSTmst-sys.comMar 2026 · $40M

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAgate Medical Investments LP SCP Vitalife Partners GV (Google Ventures)Northpond Ventures SV Health Investors

Noema Pharmanoemapharma.com inNov 2025

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)in Volker Knappertz(Executive Vice President of Research & Development)in Michael Samar(Chief Financial Officer)in Rob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartners Jeito Capital Roche Venture Fund Sofinnova Partners EQT EQT Life Sciences +2 more

Novameatnovameat.com inSep 2024

NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.

FoodTech

Giuseppe Scionti(Founder)in

Co-investorsAurum Venture Partners Carbon Sofinnova Partners Unovis Asset Management VU Venture Partners Rubio Impact Ventures

Progentos Therapeuticsprogentos.comMay 2024 · $65M

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in

Board Aleks Radovic-Moreno(Director)in Dan Janney(Director)

Co-investorsAlta Partners Longwood Fund Mission Biocapital Service Provider Capital Dolby Family Ventures

Promediorpromedior.comFeb 2012

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)in John Friedman(Director)inHarold R. Werner(Director)

Co-investorsEaston Capital Sofinnova Ventures Easton Capital Investment Group

Protegoprotegosolutions.io 𝕏Defunct

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)in

Co-investorsNovartis Venture Fund Y Combinator Glilot Capital Partners Omega Funds YK Bioventures

Protego Biopharmaprotegobio.com inDec 2025 · $130M

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDroia Ventures Novartis Venture Fund Digitalis Ventures Lightspeed Venture Partners MPM BioImpact Vida Ventures +1 more

RQ Biorqbiotechnology.comJun 2026 · $115M

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences LifeArc Ventures EQT Life Sciences Oxford Science Enterprises Wellington Management

Sidera Biosiderabio.com

Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.

Biotech

Co-investorsRA Capital Novo Holdings

Tropictropicapp.io in

Tropic is a procurement platform that gives finance and procurement teams pricing intelligence, negotiation playbooks, and expert support to reduce spend on SaaS and AI software.

AI & Machine LearningFintechSaaSNew York City, US

Justin Etkin(Founder)in David Campbell(Founder)in

Co-investorsShine Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Gyroscope Therapeutics LtdMemento Medicines Navigator Medicines Solstice OncologyVectorY

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 3

2 IPOs · 1 acquisitions

Dyne TherapeuticsNASDAQ: DYNMapLight TherapeuticsNASDAQ: MPLTInversagoacq. by Novo Nordisk

Portfolio news

latest coverage across their companies

Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year - BioSpace

Altesa BioSciences · biospace.com · Aug 25, 2026

Finance Watch: Venture Capital Investors Meet Biotechs In The Middle

Kynexis · insights.citeline.com · Aug 20, 2026

Roundup: Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements | PharmExec

MapLight Therapeutics · pharmexec.com · Aug 17, 2026

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update - BioSpace

Milestone Pharmaceuticals · biospace.com · Aug 12, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Forbion Capital · fiercebiotech.com · Aug 12, 2026

Strategy sells 1,690 BTC, raises $653M from MST... | Pluang

MST · pluang.com · Aug 10, 2026

Exosome Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

Exosome Diagnostics · globenewswire.com · Jul 7, 2026

Intellectia

Dyne Therapeutics · intellectia.ai · Jul 1, 2026

Fund performance · per public LP disclosures · 5

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Forbion BioEconomy Fund I Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.90x	0.00x
Forbion Growth Opportunities Fund III Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.65x	0.07x
Forbion Ventures Fund VII Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.85x	0.01x
Forbion Growth Opportunities Fund II Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.64x	1.01x
Forbion Ventures Fund VI Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.34x	0.34x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Forbion made?: Forbion has 48 tracked investments, 3 of which have exited, including 14 dated in the last 24 months.
What stage does Forbion invest at?: Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Forbion focus on?: Forbion focuses on AgTech, Biotech, Cleantech, Climate Tech, Healthtech, Impact & Social Good, Medical Devices.
Where is Forbion located?: Forbion is headquartered in Naarden, NL.
Does Forbion lead rounds?: Forbion has led 10 of the 22 rounds where its role is on record.
Who does Forbion co-invest with?: Forbion most often shares deals with BioMedPartners, DeepTech & Climate Fonds, Entrepreneur First, among 11 tracked co-investors.

Media · Podcasts & interviews

featuring the team

BIO-Europe® 2015: Interview with Sander Slootweg, Forbion Capital Partners

EBD Group · Sander Slootweg

Forbion Portfolio Company Spotlight Series | Episode 1: VectorY

Forbion

Message by Olivér Várhelyi on the occasion of the European Life Sciences Coalition

Forbion

Forbion 2nd Annual Excellence Roundtable: The future of innovation in rare diseases

Forbion

From Bench to Boardroom: The 2nd Annual Cambridge–Forbion Roundtable

Forbion

Forbion Patient Perspective Series | Episode 1 - What ALS can't take from Marcel

Forbion

Images

Co-investors · 41

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

Both backed · 9

Amphista CatalYm Citryll F2G Granite Bio Kynexis LoQus23 Protego Protego Biopharma

$5M – $25M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 6

Dyne Therapeutics Mariana Oncology Memento Medicines Navigator Medicines Sidera Bio Solstice Oncology

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 5

Elevara F2G Noema Pharma Novameat Purespring

$540K – $27M

BioGeneration Ventures

BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.

Both backed · 4

Azafaros CatalYm Citryll Complement Therapeutics

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 4

Coultreon Expeditiontx PromediorGyroscope Therapeutics Ltd

$100K – $15M

Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 4

Amphista Beacontx F2G Purespring

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 3

Dyne Therapeutics Mariana Oncology Pheontx

$500K – $1M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 3

Expeditiontx Granite Bio Memento Medicines

$5M

Longwood Fund

Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.

Both backed · 3

Coultreon Engrail Therapeutics Progentos Therapeutics

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 2

Gate Bio ロゴマーク：AIRNA

$50K – $250M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

Both backed · 2

Noema Pharma RQ Bio

$11M – $66M

Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

Both backed · 2

Gate Bio Granite Bio

$250K – $5M

▶29 more co-investors

Nextech Invest Ysios Capital Seroba Life Sciences New Enterprise Associates (NEA)F-Prime Capital HTGF Cambridge Innovation Capital Pivotal Life Sciences Andera Partners Seventure Partners RiverVest Venture Partners Alta Partners RTW Investments L.P.Red Tree Venture Arcus Ventures Founders Fund Polaris Partners US Venture Partners General Atlantic OrbiMed Xtripe Angels 5AM Ventures Domain Associates Third Rock Ventures Pfizer Venture Investments Kurma Partners Access Industries Inkef 4see Ventures

Firms observed investing alongside Forbion, from public investor directories. Shared companies are the overlap with Forbion's recorded portfolio.

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Innovestor Ventures

Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.

$270K – $3.2M

MDI Ventures

MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.

$500K – $75M

UntroD Capital

UntroD Capital is a deep-tech-focused investment firm that backs research-and-development-driven startups whose innovative technologies address challenges facing the planet and humanity, an approach it terms 'Real Tech'.

$772K – $241M

Sofinnova Partners

$540K – $27M